Key statistics
On Friday, Summit Therapeutics Inc (SMMT:NMQ) closed at 24.39, -28.03% below its 52-week high of 33.89, set on Sep 16, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 23.16 |
---|---|
High | 24.95 |
Low | 22.96 |
Bid | 24.39 |
Offer | 24.75 |
Previous close | 23.16 |
Average volume | 17.76m |
---|---|
Shares outstanding | 724.54m |
Free float | 102.39m |
P/E (TTM) | -- |
Market cap | 17.67bn USD |
EPS (TTM) | -0.2299 USD |
Data delayed at least 15 minutes, as of Sep 20 2024 21:00 BST.
More ▼
- PESG Releases Report on Nuvectis Pharma: With Summit Therapeutics Threatening to Dethrone Merck's Keytruda, Nuvectis' NXP900 is One to Watch
- Promising Anti-Tumor Activity and Safety of Ivonescimab in Combination Therapies in CRC, TNBC, and HNSCC Featured at ESMO 2024
- Summit Therapeutics Raises $235 Million
- Ivonescimab Monotherapy Reduced the Risk of Disease Progression or Death by 49% Compared to Pembrolizumab Monotherapy in First-Line Treatment of Patients with PD-L1 Positive Advanced NSCLC in China
- Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- HARMONi-2, Featuring Ivonescimab Monotherapy vs. Pembrolizumab Monotherapy, to be Showcased in Presidential Symposium at WCLC 2024
- Summit Therapeutics Reports Financial Results and Operational Progress for the Second Quarter and Six Months Ended June 30, 2024
- Summit Therapeutics to Host Second Quarter 2024 Financial Results & Operational Progress Call on August 6, 2024
- Summit Therapeutics and MD Anderson Announce Strategic Collaboration to Accelerate Development of Ivonescimab
- Summit Therapeutics Appoints Jeff Huber, Transformational Google and GRAIL Executive, to its Board of Directors
More ▼